Absolutely, the potential in their blood program technology alone, is staggering, imo, and there's so many more potential applications waiting in the wings for clinicals and eventual commercialization, somt that already have shown to work in other countries, like a successful stem cell procedure for repairing heart valves.
As trite as it sounds, it's just a matter of time before some event(s) triggers the attention and fascination of wall street and the general public and ACTC and other stem cell companies, nowhere as well positioned as ACTC, will explode in price, imo.
I'm trying hard not to be a pumper, but this is exciting and we're fortunate to be around during the emerging commercialization of stem cell medical applications.
News 
Market Data 
Discover 
